Influenza A Virus IgG Control Serum BC1231G

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Influenza A Virus IgG Control Serum
Applications: ELISA
IgG control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC1231G Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgG, Influenza Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Influenza A Virus reactive IgG
species reactivity	Influenza A Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Influenza A Virus IgG Control Serum BC1231G

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products Influenza A Virus IgA Control Serum (BC1231A) Influenza A Virus IgG Control Serum (BC1231G) Influenza A Virus IgM Control Serum (BC1231M) Influenza A Virus IgA ELISA Kit (ESR1231A) Influenza A Virus IgG ELISA Kit (ESR1231G) Influenza A Virus IgM ELISA Kit (ESR1231M)

target relevance

human antibody anti-Influenza Virus

Influenza Virus

Description
Virus that causes influenza (flu)

Structure
Influenza viruses are enveloped, negative-sense, single-stranded RNA viruses belonging to the Orthomyxoviridae family. The viral genome is segmented into multiple RNA molecules, allowing genetic reassortment between different strains. Influenza A and B viruses are the primary causes of seasonal influenza in humans, while Influenza A viruses also infect a wide range of animal species including birds, pigs, horses, and marine mammals. The viral envelope contains the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), which are responsible for viral attachment, entry, and release from host cells. Influenza viruses are characterized by a high mutation rate, resulting in antigenic drift and the emergence of new variants. Periodically, reassortment events between different influenza strains can result in antigenic shift, leading to the emergence of pandemic viruses.

Diagnosis
The diagnosis of influenza is performed by the detection of viral RNA, viral antigens, or influenza-specific antibodies. Molecular methods such as reverse transcription polymerase chain reaction (RT-PCR) are considered the gold standard for the detection and differentiation of influenza virus types and subtypes. Rapid influenza diagnostic tests (RIDTs) detect viral antigens and provide results within minutes but generally have lower sensitivity than molecular methods. Serological assays including ELISA and hemagglutination inhibition tests may be used to determine previous exposure, monitor immune responses, or support epidemiological investigations. Influenza-specific IgM antibodies typically appear during the acute phase of infection, while IgG antibodies develop later and may persist for years, providing varying degrees of immunity against related viral strains.

Symptoms
Influenza viruses are highly contagious respiratory pathogens that spread primarily through respiratory droplets and aerosols generated by infected individuals. Following an incubation period of approximately one to four days, influenza typically presents with abrupt onset of fever, chills, headache, myalgia, fatigue, sore throat, and dry cough. Additional symptoms may include nasal congestion, runny nose, and loss of appetite. Although most infections are self-limiting, severe disease can occur in young children, elderly individuals, pregnant women, and immunocompromised patients. Complications include viral pneumonia, secondary bacterial pneumonia, myocarditis, encephalitis, and acute respiratory distress syndrome (ARDS). Seasonal influenza is responsible for substantial morbidity and mortality worldwide, and periodic pandemics caused by novel influenza A strains can result in widespread outbreaks with significant public health impact.

Data

FAQ & Publications

Frequently Asked Questions

What are the recommended storage conditions for the Influenza A Virus IgG Control Serum BC1231G?

The Influenza A Virus IgG Control Serum BC1231G should be stored at 2-8°C to maintain stability and efficacy.

Is the Influenza A Virus IgG Control Serum BC1231G compatible with SERION ELISA assays?

Yes, this control serum is ready-to-use and pre-diluted specifically for use with SERION ELISA classic and SERION ELISA antigen assays.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC1231G protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Influenza A Virus IgG Control Serum BC1231G

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Cytomegalovirus IgG Control Serum BC109G

Brucella IgG Control Serum BC116G

Influenza B Virus IgG Control Serum BC1232G

Borrelia burgdorferi IgG Control Serum BC121G

Echovirus IgG Control Serum BC135G

Bordetella pertussis IgG Control Serum BC120G

Echinococcus IgG Control Serum BC107G

Aspergillus fumigatus IgG Control Serum BC132G

Diphtheria IgG Control Serum BC130G

Adenovirus IgG Control Serum BC128G

Coxsackie IgG Virus Control Serum BC134G

Chlamydia trachomatis IgG Control Serum BC1372G

Chlamydia pneumoniae IgG Control Serum BC1371G

Candida albicans IgG Control Serum BC117G

Campylobacter jejuni IgG Control Serum BC139G